Towards gene therapy based on femtosecond optical transfection

M. Antkowiak; M. L. Torres-Mapa; J. McGinty; M. Chahine; L. Bugeon; A. Rose; A. Finn; S. Moleirinho; K. Okuse; M. Dallman; P. French; S. E. Harding; P. Reynolds; F. Gunn-Moore; K. Dholakia

doi:10.1117/12.922835

8 May 2012 Towards gene therapy based on femtosecond optical transfection

M. Antkowiak, M. L. Torres-Mapa, J. McGinty, M. Chahine, L. Bugeon, A. Rose, A. Finn, S. Moleirinho, K. Okuse, M. Dallman, P. French, S. E. Harding, P. Reynolds, F. Gunn-Moore, K. Dholakia

Author Affiliations +

Proceedings Volume 8427, Biophotonics: Photonic Solutions for Better Health Care III; 84270R (2012) https://doi.org/10.1117/12.922835
Event: SPIE Photonics Europe, 2012, Brussels, Belgium

Abstract

Gene therapy poses a great promise in treatment and prevention of a variety of diseases. However, crucial to studying and the development of this therapeutic approach is a reliable and efficient technique of gene and drug delivery into primary cell types. These cells, freshly derived from an organ or tissue, mimic more closely the in vivo state and present more physiologically relevant information compared to cultured cell lines. However, primary cells are known to be difficult to transfect and are typically transfected using viral methods, which are not only questionable in the context of an in vivo application but rely on time consuming vector construction and may also result in cell de-differentiation and loss of functionality. At the same time, well established non-viral methods do not guarantee satisfactory efficiency and viability. Recently, optical laser mediated poration of cell membrane has received interest as a viable gene and drug delivery technique. It has been shown to deliver a variety of biomolecules and genes into cultured mammalian cells; however, its applicability to primary cells remains to be proven. We demonstrate how optical transfection can be an enabling technique in research areas, such as neuropathic pain, neurodegenerative diseases, heart failure and immune or inflammatory-related diseases. Several primary cell types are used in this study, namely cardiomyocytes, dendritic cells, and neurons. We present our recent progress in optimizing this technique's efficiency and post-treatment cell viability for these types of cells and discuss future directions towards in vivo applications.

Citation Download Citation

M. Antkowiak, M. L. Torres-Mapa, J. McGinty, M. Chahine, L. Bugeon, A. Rose, A. Finn, S. Moleirinho, K. Okuse, M. Dallman, P. French, S. E. Harding, P. Reynolds, F. Gunn-Moore, and K. Dholakia "Towards gene therapy based on femtosecond optical transfection", Proc. SPIE 8427, Biophotonics: Photonic Solutions for Better Health Care III, 84270R (8 May 2012); https://doi.org/10.1117/12.922835

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available